Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages

Abstract

Small cell lung cancer (SCLC), as a proportion, makes up only 15–17% of lung cancer cases. The development of treatments for SCLC has remained stagnant for decades, and SCLC is expected to persist as a threat to human health. To date, no publications based on large populations have been reported. We calculated survival changes in patients with SCLC during each decade between 1983 and 2012 to determine the roles of race, sex, age, and socioeconomic status (SES) on survival rates based on the Surveillance, Epidemiology, and End Results (SEER) registries. In total, 106,296 patients with SCLC were identified, with the overall incidence per 100,000 decreasing each decade from 9.6 to 7.8 to 5.8. The median survival for SCLC remained 7 months, and the 12-month relative survival rates (RSRs) remained relatively stable at 32.9%, 33.2% and 33.2% during each decade. The 5-year RSRs significantly improved from 4.9% to 5.9% to 6.4% during each decade, but remained extremely low. In addition, a narrowing of the survival gaps among SES groups and stable survival gaps between sexes were observed. Although the incidence of SCLC decreased during each decade, the overall survival remained relatively stable, highlighting the urgency of developing novel treatments and the importance of prevention and early detection.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

“…1,2 SCLC is a highly malignant form of lung cancer, and its prognosis is poor, with an estimated 5-year survival rate of only 6%. [2][3][4] Chemotherapy has been the standard of systemic treatment for SCLC for several decades; however, although SCLC is initially responsive to chemotherapy, relapse is common and the response to second-line therapy is poor, with survival of less than 6 months. 5,6 In addition, the overall median survival of patients with SCLC was found to be unchanged between 1983 and 2012, remaining at just 7 months throughout the period and thus highlighting the urgent need for novel treatments.…”

“…5,6 In addition, the overall median survival of patients with SCLC was found to be unchanged between 1983 and 2012, remaining at just 7 months throughout the period and thus highlighting the urgent need for novel treatments. 3,4 More recent studies of combination therapies, such as the addition of atezolizumab to carboplatin and etoposide chemotherapies, have demonstrated significantly longer overall survival and progression-free survival rates compared with placebo; however, the gains are modest (median 2 months' additional overall survival compared with placebo). 7 Epigenetic dysregulation is an important pathogenic mechanism in many cancers, including SCLC, 8 and therapies that target epigenetic mediators have been shown to be successful in cancer.…”

Incidence and Survival Changes in Patients with Esophageal Adenocarcinoma during 1984–2013

“…e median age at diagnosis was 65 years; accordingly, we subdivided age into five groups 45-54, 55-64, 65-74, and 75+ years). e SES level was defined as in previous publications and then divided into three levels on the basis of the county poverty rate [8]. However, we integrated the medium-and high-poverty groups into medium/high poverty because of the small sample size.…”

SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures

“…(SCLC) represents only 15% of all lung cancers, it accounts for more than 30,000 cases in the US 75 alone and has the most aggressive clinical course with most patients presenting with widely 76 metastatic disease and a median survival of 10-12 months (Wang et al, 2017). The diagnosis of 77 SCLC is based on histological features including dense sheets of small cells with scant cytoplasm, 78…”